Merck, J&J, Bristol Myers Squibb CEOs face Senate drug price hearing

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Bill Clark | Cq-roll Call, Inc. | Getty ImagesSenators are questioning the CEOs of Johnson & Johnson, Merck and...

Read more...

CVS Heath (CVS) Q4 2023 earnings

CVS Health on Wednesday reported fourth-quarter revenue and adjusted earnings that topped expectations, but the company cut its full-year profit outlook, citing higher medical costs that are dogging the broader insurance industry.The company lowered its 2024 adjusted earnings forecast to at least $8.30 per share, down from a previous...

Read more...

Novo Nordisk parent to buy Catalent to expand Wegovy supply

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. Victoria Klesty | ReutersNovo Nordisk's parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly...

Read more...

Biogen drops Alzheimer’s drug Aduhelm to focus on Leqembi, others

The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023.Vanessa Leroy | Bloomberg | Getty ImagesBiogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus...

Read more...

GSK posts blowout RSV vaccine sales, raises outlook

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | ReutersGlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine.The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or...

Read more...

Vertex non-opioid painkiller shows positive late-stage trial results

A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019.Brian Snyder | ReutersVertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trialsThe drug, known as VX-548,...

Read more...